A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
30 11 2022
Historique:
pubmed: 26 3 2022
medline: 15 6 2022
entrez: 25 3 2022
Statut: ppublish

Résumé

The current scenario of typhoid fever warrants early prevention with typhoid conjugate vaccines in susceptible populations to provide lifelong protection. We conducted a multicenter, single-blind, randomized, Phase 2/3 study to assess the immunogenicity and safety of Biological E's Typhoid Vi-CRM

Identifiants

pubmed: 35333702
doi: 10.1080/21645515.2022.2043103
pmc: PMC9196756
doi:

Substances chimiques

Typhoid-Paratyphoid Vaccines 0
Vaccines, Conjugate 0

Types de publication

Clinical Trial, Phase II Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2043103

Références

Trop Med Int Health. 2016 Oct;21(10):1255-1262
pubmed: 27495900
Indian J Med Res. 2020 Jan;151(1):22-34
pubmed: 32134011
Lancet Infect Dis. 2014 Feb;14(2):119-29
pubmed: 24290843
Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S141-S150
pubmed: 32725225
Indian J Med Res. 2019 Nov;150(5):437-447
pubmed: 31939387
Bull World Health Organ. 2008 Apr;86(4):260-8
pubmed: 18438514
Cochrane Database Syst Rev. 2018 May 31;5:CD001261
pubmed: 29851031
Lancet. 2015 Mar 21;385(9973):1136-45
pubmed: 25458731
Hum Vaccin. 2011 Aug;7(8):883-5
pubmed: 21791973
Vaccine. 1999 Oct 1;17 Suppl 2:S22-7
pubmed: 10506405
Expert Rev Vaccines. 2013 Nov;12(11):1273-86
pubmed: 24156285
Lancet Infect Dis. 2019 Jan;19(1):e26-e30
pubmed: 30170987
Vaccine. 2012 Sep 21;30(43):6111-4
pubmed: 22705173
J Clin Diagn Res. 2015 May;9(5):SC01-3
pubmed: 26155525
Acta Medica (Hradec Kralove). 2018;61(4):125-130
pubmed: 30664444
Lancet Glob Health. 2017 Mar;5(3):e310-e323
pubmed: 28193398
Lancet. 1999 Aug 28;354(9180):734-7
pubmed: 10475185
PLoS One. 2011;6(9):e25398
pubmed: 21980445
Emerg Infect Dis. 2005 Feb;11(2):326-9
pubmed: 15752457
Vaccine. 2021 May 6;39(19):2620-2627
pubmed: 33849723
Lancet Infect Dis. 2019 Apr;19(4):369-381
pubmed: 30792131
BMC Public Health. 2018 May 3;18(1):594
pubmed: 29724223
Vaccine. 2019 Jan 7;37(2):214-216
pubmed: 29661581
Vaccines (Basel). 2018 Jul 24;6(3):
pubmed: 30042307
N Engl J Med. 2009 Jul 23;361(4):335-44
pubmed: 19625715
Vaccine. 2011 Jan 17;29(4):712-20
pubmed: 21115057
J Glob Health. 2015 Dec;5(2):020407
pubmed: 26649174
Indian Pediatr. 2021 Jan 15;58(1):44-53
pubmed: 33257602

Auteurs

Subhash Thuluva (S)

Clinical Development Department, Biological E Limited, Hyderabad, India.

Vikram Paradkar (V)

Clinical Development Department, Biological E Limited, Hyderabad, India.

Ramesh Matur (R)

Clinical Development Department, Biological E Limited, Hyderabad, India.

Kishore Turaga (K)

Clinical Development Department, Biological E Limited, Hyderabad, India.

Subba Reddy Gv (SR)

Clinical Development Department, Biological E Limited, Hyderabad, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH